Evidence map›Paper›PMID 39708331›Full record

ArticleAnnals of clinical and translational neurology2025

Alpha-synuclein RT-QuIC assay in gastroduodenal and skin biopsies of Parkinson disease patients.

Aron Emmi, Angela Mammana, Michele Sandre, Simone Baiardi, Luca Weis, Marcello Rossi, Franco Magliocchetti, Edoardo Savarino, Francesco Paolo Russo, Andrea Porzionato and 4 more

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aron Emmi *Parkinson and Movement Disorders Unit, Department of Neuroscience, Centre for Rare Neurological Diseases (ERN-RND), University of Padova, Padova, Italy.
Angela Mammana *IRCCS, Istituto delle Scienze Neurologiche di Bologna (ISNB), Bologna, Italy.
Michele SandreParkinson and Movement Disorders Unit, Department of Neuroscience, Centre for Rare Neurological Diseases (ERN-RND), University of Padova, Padova, Italy.
Simone BaiardiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Luca WeisInstitute of Hospitalization and Care of a Scientific Nature (IRCCS), IRCCS San Camillo Hospital, Venezia, Italy.
Marcello RossiIRCCS, Istituto delle Scienze Neurologiche di Bologna (ISNB), Bologna, Italy.
Franco MagliocchettiIRCCS, Istituto delle Scienze Neurologiche di Bologna (ISNB), Bologna, Italy.
Edoardo SavarinoDepartment of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy.
Francesco Paolo RussoDepartment of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy.
Andrea PorzionatoCenter for Neurodegenerative Disease Research (CESNE), University of Padova, Padova, Italy.
Miryam CarecchioParkinson and Movement Disorders Unit, Department of Neuroscience, Centre for Rare Neurological Diseases (ERN-RND), University of Padova, Padova, Italy.ORCID 0000-0002-0755-5477
Marta CampagnoloParkinson and Movement Disorders Unit, Department of Neuroscience, Centre for Rare Neurological Diseases (ERN-RND), University of Padova, Padova, Italy.ORCID 0000-0002-6394-7168
Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, Centre for Rare Neurological Diseases (ERN-RND), University of Padova, Padova, Italy.
Piero ParchiIRCCS, Istituto delle Scienze Neurologiche di Bologna (ISNB), Bologna, Italy.ORCID 0000-0002-9444-9524

Funding

National Recovery and Resilience Plan (NRRP) - the Next Generation EU - National Center for Gene Therapy and Drugs based on RNA TechnologyRicerca Finalizzata-2021-12374386, funded by the Ministry of Healththe National Recovery and Resilience Plan, Investment PE8 - Project Age-It: "Ageing Well in an Ageing Society"the #NextGenerationEU (NGEU) project MNESYS (PE0000006), funded by the Ministry of University and Research (MUR)
6 · The paper itself

Abstract

In this study, we compared the value of pathological alpha-synuclein (αSyn) seed amplification assay (SAA) in gastric and duodenal biopsies with skin biopsies in Parkinson disease (PD) patients with different disease duration. The accuracy of αSyn SAA was 87.7% in skin, 67.4% in duodenum, and 80.0% in gastric biopsies, with significantly higher sensitivity in advanced PD (skin: 81.8%; gastric: 88.9%; duodenal 58.8%). Misfolded αSyn was detected with higher sensitivity in advanced PD across all matrices, likely reflecting the progression of αSyn pathology. The seeding activity was lower in the duodenal than in the gastric wall, indicating differences in αSyn burden.

Indexed as

alpha-SynucleinDuodenumGastric MucosaParkinson DiseaseSkinAgedBiopsyFemaleHumansMaleMiddle Agedalpha-SynucleinSNCA protein, human

Identifiers

PMID39708331
PMCPMC11920727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.